Volume 51, Issue 5

Search all European Journal of Nuclear Medicine and Molecular Imaging articles

April 2024

37 articles in this issue

A. Zaheer, S.P. Raman, M.L. Rosado-de-Christenson, S. Martínez-Jiménez, S.H. Garrana, G. Fananapazir, D. Rogers, B.R. Foster: Imaging Anatomy: Chest, Abdomen, Pelvis, 3rd Edition
Luigi Mansi
Book Review 10 January 2024 Pages: 1201 - 1202
After one year of ChatGPT’s launch: reflections on artificial intelligence in scientific writing
Yuan Feng
Jinquan Han
Xiaoli Lan
Editorial 18 January 2024 Pages: 1203 - 1204
Advances in targeted alpha therapy of cancer
Mike Sathekge
Alfred Morgenstern
Editorial 20 February 2024 Pages: 1205 - 1206
Part of 1 collection:

Alpha Therapy
Alpha emitter isotopes and PSMA ligands: the near future therapeutic prospective for castration-resistant prostate cancer
Fabio Volpe
Leandra Piscopo
Michele Klain
Editorial 23 December 2023 Pages: 1207 - 1209
Beyond stillness: the importance of tackling patient’s motion for reliable parametric imaging
Alessia Artesani
Laura Providência
Charalampos Tsoumpas
Editorial 13 January 2024 Pages: 1210 - 1212
Letter to the Editor: FDG Liver Biodistribution
Dale L. Bailey
Geoffrey P. Schembri
Paul J. Roach
Letter to the Editor 23 February 2024 Pages: 1213 - 1214
Ultra-fast whole-body bone tomoscintigraphies achieved with a high-sensitivity 360° CZT camera and a dedicated deep-learning noise reduction algorithm
Achraf Bahloul
Antoine Verger
Laetitia Imbert
Short Communication 12 December 2023 Pages: 1215 - 1220
[¹⁷⁷Lu]Lu-labeled anti-claudin-18.2 antibody demonstrated radioimmunotherapy potential in gastric cancer mouse xenograft models
Ziqing Zeng
Liqiang Li
Hua Zhu
Original Article 08 December 2023 Pages: 1221 - 1232
Part of 1 collection:

Preclinical Molecular Imaging and Cancer Theranostics
Adhesion molecule–targeted magnetic particle imaging nanoprobe for visualization of inflammation in acute lung injury
Pengli Gao
Yu Liu
Jie Tian
Original Article 14 December 2023 Pages: 1233 - 1245
Theranostic role of ⁸⁹Zr- and ¹⁷⁷Lu-labeled aflibercept in breast cancer
Qi Yang
Zhao Chen
Lei Kang
Original Article 23 December 2023 Pages: 1246 - 1260
Part of 1 collection:

Preclinical Molecular Imaging and Cancer Theranostics
Detection of metabolic adaptation in a triple-negative breast cancer animal model with [¹⁸F]choline-PET imaging as a surrogate for drug resistance
Andres A. Kohan
Mathieu Lupien
Patrick Veit-Haibach
Short Communication 14 December 2023 Pages: 1261 - 1267
EANM guidance document: dosimetry for first-in-human studies and early phase clinical trials
Caroline Stokke
Silvano Gnesin
Jonathan Gear
Guidelines Open access 17 February 2024 Pages: 1268 - 1286
FDG-PET/CT for investigation of pyrexia of unknown origin: a cost of illness analysis
Bonnia Liu
Ronald Ma
Andrew M. Scott
Original Article 07 December 2023 Pages: 1287 - 1296
[¹⁸F]FDG PET/CT for therapeutic assessment of Abatacept in early-onset polymyalgia rheumatica
Bastien Allard
Valérie Devauchelle-Pensec
Solène Querellou
Original Article 14 December 2023 Pages: 1297 - 1309
High-temporal resolution functional PET/MRI reveals coupling between human metabolic and hemodynamic brain response
Andreas Hahn
Murray B. Reed
Rupert Lanzenberger
Original Article Open access 06 December 2023 Pages: 1310 - 1322
Effects of medication on dopamine transporter imaging using [¹²³I]I-FP-CIT SPECT in routine practice
Yuliya Piatkova
Matthieu Doyen
Antoine Verger
Original Article 20 December 2023 Pages: 1323 - 1332
Automated identification of uncertain cases in deep learning-based classification of dopamine transporter SPECT to improve clinical utility and acceptance
Thomas Budenkotte
Ivayla Apostolova
Ralph Buchert
Original Article Open access 22 December 2023 Pages: 1333 - 1344
Expanding the clinical indications of [¹⁸F]fluorocholine PET/CT in primary hyperparathyroidism: the evidence cannot be evaded
Giorgio Treglia
Alessio Rizzo
Arnoldo Piccardo
Editorial 23 December 2023 Pages: 1345 - 1348
Performance of [¹⁸F]fluorocholine PET/CT in MEN1-related primary hyperparathyroidism before initial surgery or for persistent/recurrent disease
Aymeric Boucher
Julia Delabie
David Taïeb
Original Article 07 December 2023 Pages: 1349 - 1360
Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapy
Conrad-Amadeus Voltin
Andrea Paccagnella
Christine Hanoun
Original Article Open access 20 December 2023 Pages: 1361 - 1370
Dynamic total-body PET/CT imaging with reduced acquisition time shows acceptable performance in quantification of [¹⁸F]FDG tumor kinetic metrics
Guobing Liu
Yimeng Shi
Hongcheng Shi
Original Article 11 December 2023 Pages: 1371 - 1382
CXCR4-directed PET/CT with [⁶⁸ Ga]Ga-pentixafor in solid tumors—a comprehensive analysis of imaging findings and comparison with histopathology
Niklas Dreher
Stefanie Hahner
Rudolf A. Werner
Original Article Open access 12 December 2023 Pages: 1383 - 1394
Pre-clinical evaluation of biomarkers for the early detection of nephrotoxicity following alpha-particle radioligand therapy
Mengshi Li
Claudia Robles-Planells
Diana Zepeda-Orozco
Original Article Open access 14 December 2023 Pages: 1395 - 1408
Therapeutic efficacy of an alpha-particle emitter labeled anti-GD2 humanized antibody against osteosarcoma—a proof of concept study
Ioanna Liatsou
Yingli Fu
George Sgouros
Original Article 18 December 2023 Pages: 1409 - 1420
Molecular imaging of IDH-mutant gliomas in the new era of IDH inhibitors: preparing for future challenges
Gaia Ninatti
Rosa Maria Moresco
Martina Sollini
Editorial 09 January 2024 Pages: 1421 - 1422
Development and validation of clinical-radiomics analysis for preoperative prediction of IDH mutation status and WHO grade in diffuse gliomas: a consecutive l-[methyl-11C] methionine cohort study with two PET scanners
Weiyan Zhou
Jianbo Wen
Tao Hua
Original Article 19 December 2023 Pages: 1423 - 1435
Part of 1 collection:

Preclinical Molecular Imaging and Cancer Theranostics
The clinical acceptability of short versus long duration acquisitions for head and neck cancer using long-axial field-of-view PET/CT: a retrospective evaluation
Riccardo Mei
Thomas Pyka
Ian Alberts
Original Article Open access 14 December 2023 Pages: 1436 - 1443
Comparative assessment of radiation therapy–induced vasculitis using [¹⁸F]FDG-PET/CT in patients with non-small cell lung cancer treated with proton versus photon radiotherapy
D. Evanson
M. Griffin
A. Alavi
Original Article Open access 14 December 2023 Pages: 1444 - 1450
Prediction of therapy response of breast cancer patients with machine learning based on clinical data and imaging data derived from breast [¹⁸F]FDG-PET/MRI
Kai Jannusch
Frederic Dietzel
Julian Caspers
Original Article Open access 22 December 2023 Pages: 1451 - 1461
The EANM Focus 5 consensus on ‘molecular imaging and theranostics in prostate cancer’: the future begins today
Daniela-Elena Oprea-Lager
Steven MacLennan
Stefano Fanti
Editorial 27 January 2024 Pages: 1462 - 1463
Incorporating the [68Ga]Ga-PSMA PET/CT PRIMARY score into the selection criteria for prostate cancer patients eligible for active surveillance
Levent Kabasakal
Ruştu Turkay
Bulent Onal
Editorial 12 February 2024 Pages: 1464 - 1466
Prediction of clinically significant prostate cancer by [⁶⁸ Ga]Ga-PSMA-11 PET/CT: a potential tool for selecting patients for active surveillance
Kaan Akcay
Ali Kibar
Levent Kabasakal
Original Article 19 December 2023 Pages: 1467 - 1475
A convolutional neural network–based system for fully automatic segmentation of whole-body [⁶⁸Ga]Ga-PSMA PET images in prostate cancer
Esmail Jafari
Amin Zarei
Majid Assadi
Original Article 14 December 2023 Pages: 1476 - 1487
Intense PSMA expression of the uvula detected by [⁶⁸ Ga]Ga-PSMA-PET/CT
Lisa Glantschnig
Alexander Dierks
Malte Kircher
Image of the Month Open access 13 November 2023 Pages: 1488 - 1489
First-in-human SPECT/CT imaging of [²¹²Pb]Pb-VMT-α-NET in a patient with metastatic neuroendocrine tumor
Enrico Michler
David Kästner
Jörg Kotzerke
Image of the Month Open access 22 November 2023 Pages: 1490 - 1492
Impact of patient motion on parametric PET imaging
Alessia Artesani
Joyce van Sluis
Charalampos Tsoumpas
Image of the Month Open access 15 January 2024 Pages: 1493 - 1494
Correction to: Theranostic role of ⁸⁹Zr‑ and ¹⁷⁷Lu‑labeled aflibercept in breast cancer
Qi Yang
Zhao Chen
Lei Kang
Correction 12 January 2024 Pages: 1495 - 1495

Volume 51, Issue 5

A. Zaheer, S.P. Raman, M.L. Rosado-de-Christenson, S. Martínez-Jiménez, S.H. Garrana, G. Fananapazir, D. Rogers, B.R. Foster: Imaging Anatomy: Chest, Abdomen, Pelvis, 3rd Edition

After one year of ChatGPT’s launch: reflections on artificial intelligence in scientific writing

Advances in targeted alpha therapy of cancer

Alpha emitter isotopes and PSMA ligands: the near future therapeutic prospective for castration-resistant prostate cancer

Beyond stillness: the importance of tackling patient’s motion for reliable parametric imaging

Letter to the Editor: FDG Liver Biodistribution

Ultra-fast whole-body bone tomoscintigraphies achieved with a high-sensitivity 360° CZT camera and a dedicated deep-learning noise reduction algorithm

[¹⁷⁷Lu]Lu-labeled anti-claudin-18.2 antibody demonstrated radioimmunotherapy potential in gastric cancer mouse xenograft models

Adhesion molecule–targeted magnetic particle imaging nanoprobe for visualization of inflammation in acute lung injury

Theranostic role of ⁸⁹Zr- and ¹⁷⁷Lu-labeled aflibercept in breast cancer

Detection of metabolic adaptation in a triple-negative breast cancer animal model with [¹⁸F]choline-PET imaging as a surrogate for drug resistance

EANM guidance document: dosimetry for first-in-human studies and early phase clinical trials

FDG-PET/CT for investigation of pyrexia of unknown origin: a cost of illness analysis

[¹⁸F]FDG PET/CT for therapeutic assessment of Abatacept in early-onset polymyalgia rheumatica

High-temporal resolution functional PET/MRI reveals coupling between human metabolic and hemodynamic brain response

Effects of medication on dopamine transporter imaging using [¹²³I]I-FP-CIT SPECT in routine practice

Automated identification of uncertain cases in deep learning-based classification of dopamine transporter SPECT to improve clinical utility and acceptance

Expanding the clinical indications of [¹⁸F]fluorocholine PET/CT in primary hyperparathyroidism: the evidence cannot be evaded

Performance of [¹⁸F]fluorocholine PET/CT in MEN1-related primary hyperparathyroidism before initial surgery or for persistent/recurrent disease

Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapy

Dynamic total-body PET/CT imaging with reduced acquisition time shows acceptable performance in quantification of [¹⁸F]FDG tumor kinetic metrics

CXCR4-directed PET/CT with [⁶⁸ Ga]Ga-pentixafor in solid tumors—a comprehensive analysis of imaging findings and comparison with histopathology

Pre-clinical evaluation of biomarkers for the early detection of nephrotoxicity following alpha-particle radioligand therapy

Therapeutic efficacy of an alpha-particle emitter labeled anti-GD2 humanized antibody against osteosarcoma—a proof of concept study

Molecular imaging of IDH-mutant gliomas in the new era of IDH inhibitors: preparing for future challenges

Development and validation of clinical-radiomics analysis for preoperative prediction of IDH mutation status and WHO grade in diffuse gliomas: a consecutive l-[methyl-11C] methionine cohort study with two PET scanners

The clinical acceptability of short versus long duration acquisitions for head and neck cancer using long-axial field-of-view PET/CT: a retrospective evaluation

Comparative assessment of radiation therapy–induced vasculitis using [¹⁸F]FDG-PET/CT in patients with non-small cell lung cancer treated with proton versus photon radiotherapy

Prediction of therapy response of breast cancer patients with machine learning based on clinical data and imaging data derived from breast [¹⁸F]FDG-PET/MRI

The EANM Focus 5 consensus on ‘molecular imaging and theranostics in prostate cancer’: the future begins today

Incorporating the [68Ga]Ga-PSMA PET/CT PRIMARY score into the selection criteria for prostate cancer patients eligible for active surveillance

Prediction of clinically significant prostate cancer by [⁶⁸ Ga]Ga-PSMA-11 PET/CT: a potential tool for selecting patients for active surveillance

A convolutional neural network–based system for fully automatic segmentation of whole-body [⁶⁸Ga]Ga-PSMA PET images in prostate cancer

Intense PSMA expression of the uvula detected by [⁶⁸ Ga]Ga-PSMA-PET/CT

First-in-human SPECT/CT imaging of [²¹²Pb]Pb-VMT-α-NET in a patient with metastatic neuroendocrine tumor

Impact of patient motion on parametric PET imaging

Correction to: Theranostic role of ⁸⁹Zr‑ and ¹⁷⁷Lu‑labeled aflibercept in breast cancer

Navigation